Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of YL202 in Advanced Breast Cancer With TNBC or HR-positive, HER2-zero/low Disease
ChiCTR2400089158Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of YL202 in breast cancer (3 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate (ORR). Started Sep 2024; status: recruiting.
02
Drugs
YL202
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400089158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089158.